SRRK insider buying and SEC filings, explained
Scholar Rock Holding Corp · CIK 1727196
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$13.2M
Insiders who bought
1
Sold (not marked 10b5-1)
$10.6M
Planned sales (10b5-1)
$8.8M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 23–26, 2026 | Purchase (code P) | Srinivas Akkaraju (Director) bought 289,470 shares indirectly (by entity) between Oct 23 and Oct 26 at about $41.45 ($12.0M), reported as a purchase (code P). Holdings by entity up 36% to 723,020 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 27, 2026, 7:47 PM ET |
| Jul 1, 2026 | Planned (10b5-1) | Jeffrey S. Flier (Director) sold 3,053 shares at about $53.88 ($164K), marked as a 10b5-1 plan trade. Holdings down 10% to 27,856 shares. | SEC filing Filed Jul 6, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Michael Gilman (Director) sold 2,544 shares at about $53.87 ($137K), marked as a 10b5-1 plan trade. Holdings down 4% to 59,511 shares. | SEC filing Filed Jul 6, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Kristina Burow (Director) sold 3,053 shares at about $53.74 ($164K), marked as a 10b5-1 plan trade. Holdings down 3% to 114,657 shares. | SEC filing Filed Jul 6, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Joshua Reed (Director) sold 3,053 shares at about $53.74 ($164K), marked as a 10b5-1 plan trade. Holdings down 14% to 19,518 shares. | SEC filing Filed Jul 6, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Katie Peng (Director) sold 5,446 shares at about $53.87 ($293K), marked as a 10b5-1 plan trade. Holdings down 14% to 34,301 shares. | SEC filing Filed Jul 6, 2026 |
| Apr 16, 2026 | Sale | Keith Woods (President / COO) sold 10,220 shares at $49.57 ($507K). Holdings down 2% to 620,055 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 20, 2026 |
| Apr 16, 2026 | Sale | Akshay Vaishnaw (President / COO and Director) sold 12,246 shares at $49.57 ($607K). Holdings down 2% to 630,542 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 20, 2026 |
| Apr 16, 2026 | Sale | Vikas Sinha (CFO) sold 10,410 shares at $49.57 ($516K). Holdings down 2% to 619,856 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 20, 2026 |
| Apr 16, 2026 | Sale | David Hallal (CEO and Director) sold 30,615 shares at $49.57 ($1.5M). Holdings down 2% to 1,639,034 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 20, 2026 |
| Feb 23, 2026 | Planned (10b5-1) | Mo Qatanani (Chief Scientific Officer) sold 8,484 shares at about $47.07 ($399K), marked as a 10b5-1 plan trade. Holdings down 8% to 98,445 shares. | SEC filing Filed Feb 25, 2026 |
| Feb 17, 2026 | Sale | Mo Qatanani (Chief Scientific Officer) sold 7,989 shares at $46.53 ($372K). Holdings down 7% to 106,929 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 19, 2026 |
| Feb 17, 2026 | Sale | Caryn Parlavecchio (CHRO) sold 9,035 shares at $46.53 ($420K). Holdings down 5% to 169,087 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 19, 2026 |
| Feb 17, 2026 | Sale | Junlin Ho (General Counsel) sold 9,580 shares at $46.53 ($446K). Holdings down 4% to 241,545 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 19, 2026 |
| Feb 17, 2026 | Sale | Jing L. Marantz (Chief Medical Officer) sold 4,157 shares at $46.53 ($193K). Holdings down 3% to 126,012 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 19, 2026 |
| Jan 22, 2026 | Planned (10b5-1) | Mo Qatanani (Chief Scientific Officer) sold 14,898 shares at about $46.71 ($696K), marked as a 10b5-1 plan trade. Holdings down 15% to 85,660 shares. | SEC filing Filed Jan 23, 2026 |
| Jan 16, 2026 | Sale | Mo Qatanani (Chief Scientific Officer) sold 8,406 shares at $44.48 ($374K). Holdings down 8% to 100,558 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Jan 16, 2026 | Sale | Caryn Parlavecchio (CHRO) sold 6,600 shares at $44.48 ($294K). Holdings down 4% to 148,864 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Jan 16, 2026 | Sale | Junlin Ho (General Counsel) sold 8,016 shares at $44.48 ($357K). Holdings down 4% to 214,553 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Jan 16, 2026 | Sale | Jing L. Marantz (Chief Medical Officer) sold 5,798 shares at $44.48 ($258K). Holdings down 6% to 95,687 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Jan 14, 2026 | Planned (10b5-1) | Mo Qatanani (Chief Scientific Officer) sold 13,112 shares at about $45.20 ($593K), marked as a 10b5-1 plan trade. Holdings down 11% to 108,964 shares. | SEC filing Filed Jan 16, 2026 |
| Jan 13, 2026 | Sale | Vikas Sinha (CFO) sold 16,755 shares at $42.70 ($715K). Holdings down 3% to 583,245 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 15, 2026 |
| Jan 13, 2026 | Sale | Keith Woods (President / COO) sold 16,746 shares at $42.70 ($715K). Holdings down 3% to 583,254 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 15, 2026 |
| Jan 13, 2026 | Sale | Akshay Vaishnaw (President / COO and Director) sold 20,438 shares at $42.70 ($873K). Holdings down 3% to 595,767 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 15, 2026 |
| Jan 13, 2026 | Sale | David Hallal (CEO and Director) sold 57,450 shares at $42.70 ($2.5M). Holdings down 4% to 1,541,645 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 15, 2026 |
| Dec 16, 2025 | Planned (10b5-1) | Katie Peng (Director) sold 1,006 shares at about $44.09 ($44K), marked as a 10b5-1 plan trade. Holdings down 3% to 32,908 shares. | SEC filing Filed Dec 18, 2025 |
| Oct 7, 2025 | Purchase (code P) | Srinivas Akkaraju (Director) bought 29,599 shares indirectly (by entity) at about $39.92 ($1.2M), reported as a purchase (code P). Holdings by entity up 6% to 530,038 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 16, 2025 |
| Dec 4, 2025 | Planned (10b5-1) | Mo Qatanani (Chief Scientific Officer) sold 136,462 shares at about $45.21 ($6.2M), marked as a 10b5-1 plan trade. Holdings down 56% to 108,964 shares. | SEC filing Filed Dec 5, 2025 |
22 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow SRRK in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.